Shares of Chimerix hit a new 52-week high Tuesday after the biopharmaceutical company said the Food and Drug Administration granted a priority review for its proposed dordaviprone treatment for a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback